Loading...
•
Dec 31, 2023
Cabaletta Bio Q4 2023 Earnings Report
Cabaletta Bio reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
Key Takeaways
Cabaletta Bio reported its Q4 and full year 2023 financial results. The company's cash, cash equivalents, and short-term investments totaled $241.2 million as of December 31, 2023, which is expected to fund operations into the first half of 2026. The first patient has been dosed with CABA-201 in the RESET™ clinical trial program.
First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program
Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ trials anticipated in 1H24; longer term follow-up on these and additional patients to be reported in 2H24
RESET-SSc™ (systemic sclerosis) and RESET-MG™ trials initial clinical data anticipated to be reported in 2H24
Rare Pediatric Disease designation granted by FDA for CABA-201 in juvenile dermatomyositis
Cabaletta Bio
Cabaletta Bio
Forward Guidance
Cabaletta Bio expects that its cash, cash equivalents and short-term investments as of December 31, 2023, will enable it to fund its operating plan into the first half of 2026.